• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Steroids and 5-aminosalicylic acids in moderate ulcerative colitis: addressing the dilemma.中重度溃疡性结肠炎的类固醇和 5-氨基水杨酸:解决困境。
Therap Adv Gastroenterol. 2013 Jan;6(1):33-8. doi: 10.1177/1756283X12461395.
2
[Aminosalicylates and steroids in the treatment ot chronic inflammatory bowel diseases--consensus paper of the Working Group for Chronic Inflammatory Bowel Diseases of the OGGH].[氨基水杨酸类药物和类固醇药物治疗慢性炎症性肠病——奥地利胃肠病学会慢性炎症性肠病工作组共识文件]
Z Gastroenterol. 2006 Jun;44(6):525-38; discussion 539. doi: 10.1055/s-2006-926796.
3
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.口服5-氨基水杨酸诱导溃疡性结肠炎缓解
Cochrane Database Syst Rev. 2016 Apr 21;4(4):CD000543. doi: 10.1002/14651858.CD000543.pub4.
4
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.口服5-氨基水杨酸诱导溃疡性结肠炎缓解
Cochrane Database Syst Rev. 2012 Oct 17;10:CD000543. doi: 10.1002/14651858.CD000543.pub3.
5
Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.用于治疗炎症性肠病的药物的风险效益评估。
Drug Saf. 1991 May-Jun;6(3):192-219. doi: 10.2165/00002018-199106030-00005.
6
Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.与溃疡性结肠炎相关的泛发性坏疽性脓皮病:英夫利昔单抗和硫唑嘌呤治疗成功
Acta Dermatovenerol Croat. 2016 Apr;24(1):83-5.
7
Review article: induction therapy for patients with active ulcerative colitis.综述文章:活动性溃疡性结肠炎患者的诱导治疗
Aliment Pharmacol Ther. 2006 Sep;24 Suppl 1:10-6. doi: 10.1111/j.1365-2036.2006.03070.x.
8
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.口服5-氨基水杨酸用于维持溃疡性结肠炎缓解
Cochrane Database Syst Rev. 2012 Oct 17;10:CD000544. doi: 10.1002/14651858.CD000544.pub3.
9
Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review.中重度炎症性肠病的常规治疗:系统文献回顾。
World J Gastroenterol. 2019 Mar 7;25(9):1142-1157. doi: 10.3748/wjg.v25.i9.1142.
10
How important is onset of action in ulcerative colitis therapy?在溃疡性结肠炎治疗中,起效时间有多重要?
Drugs. 2005;65(15):2069-83. doi: 10.2165/00003495-200565150-00001.

引用本文的文献

1
Etrasimod as a Monotherapy or With Concomitant Use of Corticosteroids and/or Aminosalicylates: Results From the ELEVATE UC Clinical Program.艾曲莫德单药治疗或与皮质类固醇和/或氨基水杨酸类药物联合使用:ELEVATE UC临床项目的结果
Inflamm Bowel Dis. 2024 Dec 13. doi: 10.1093/ibd/izae288.
2
Early resolution of bowel urgency by budesonide foam enema results in improved quality of life in patients with ulcerative colitis: a multicenter prospective observational study.布地奈德泡沫灌肠剂可使溃疡性结肠炎患者的肠道急迫感早期缓解,从而改善其生活质量:一项多中心前瞻性观察研究。
Intest Res. 2025 Apr;23(2):157-169. doi: 10.5217/ir.2024.00005. Epub 2024 Jul 15.
3
Preventive Anti-inflammatory Effects of Apocynin on Acetic Acid-Induced Colitis in Rats.阿朴酯素对乙酸诱导的大鼠结肠炎的预防抗炎作用。
Inflammation. 2024 Feb;47(1):438-453. doi: 10.1007/s10753-023-01920-4. Epub 2023 Oct 26.
4
Ophiopogonin D Inhibiting Epithelial NF-κB Signaling Pathway Protects Against Experimental Colitis in Mice.麦冬皂苷D抑制上皮NF-κB信号通路对小鼠实验性结肠炎具有保护作用。
Inflammation. 2022 Aug;45(4):1720-1731. doi: 10.1007/s10753-022-01655-8. Epub 2022 Apr 23.
5
Natural compounds as safe therapeutic options for ulcerative colitis.天然化合物作为溃疡性结肠炎的安全治疗选择。
Inflammopharmacology. 2022 Apr;30(2):397-434. doi: 10.1007/s10787-022-00931-1. Epub 2022 Feb 25.
6
Extract Attenuates Dextran Sodium Sulfate-Induced Acute Colitis in Mice by Inhibiting Macrophage Activation and Monocyte Chemotaxis.提取物通过抑制巨噬细胞活化和单核细胞趋化作用减轻葡聚糖硫酸钠诱导的小鼠急性结肠炎。
Front Pharmacol. 2021 Sep 20;12:738139. doi: 10.3389/fphar.2021.738139. eCollection 2021.
7
Colitis and Crohn's Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease.印度结肠炎与克罗恩病基金会关于5-氨基水杨酸在炎症性肠病中应用的共识声明
Intest Res. 2020 Oct;18(4):355-378. doi: 10.5217/ir.2019.09176. Epub 2020 Jul 13.
8
British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.英国胃肠病学会成人炎症性肠病管理共识指南。
Gut. 2019 Dec;68(Suppl 3):s1-s106. doi: 10.1136/gutjnl-2019-318484. Epub 2019 Sep 27.
9
Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults.成人炎症性肠病的药物治疗和非药物治疗方法
World J Gastrointest Pharmacol Ther. 2016 Feb 6;7(1):5-20. doi: 10.4292/wjgpt.v7.i1.5.
10
Aligning oral mesalazine treatment to health service priorities: guidance for nurses.使口服美沙拉嗪治疗符合医疗服务优先事项:护士指南
Frontline Gastroenterol. 2014 Apr;5(2):135-142. doi: 10.1136/flgastro-2013-100357. Epub 2013 Oct 4.

本文引用的文献

1
Guidelines for the management of inflammatory bowel disease in adults.成人炎症性肠病管理指南。
Gut. 2011 May;60(5):571-607. doi: 10.1136/gut.2010.224154.
2
Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis.糖皮质激素治疗炎症性肠病:系统评价和荟萃分析。
Am J Gastroenterol. 2011 Apr;106(4):590-9; quiz 600. doi: 10.1038/ajg.2011.70. Epub 2011 Mar 15.
3
Randomised clinical trial: early assessment after 2 weeks of high-dose mesalazine for moderately active ulcerative colitis - new light on a familiar question.随机临床试验:中重度溃疡性结肠炎高剂量美沙拉嗪治疗 2 周后的早期评估 - 一个熟悉问题的新视角。
Aliment Pharmacol Ther. 2011 May;33(9):1028-35. doi: 10.1111/j.1365-2036.2011.04620.x. Epub 2011 Mar 8.
4
European evidence-based Consensus on the management of ulcerative colitis: Current management.欧洲溃疡性结肠炎管理循证共识:当前管理措施
J Crohns Colitis. 2008 Mar;2(1):24-62. doi: 10.1016/j.crohns.2007.11.002. Epub 2008 Jan 18.
5
European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis.欧洲溃疡性结肠炎诊断与管理循证共识:定义与诊断
J Crohns Colitis. 2008 Mar;2(1):1-23. doi: 10.1016/j.crohns.2007.11.001. Epub 2008 Jan 18.
6
Review article: understanding adherence to medication in ulcerative colitis - innovative thinking and evolving concepts.综述文章:理解溃疡性结肠炎患者的药物依从性——创新思维和不断发展的概念。
Aliment Pharmacol Ther. 2010 Nov;32(9):1051-8. doi: 10.1111/j.1365-2036.2010.04445.x. Epub 2010 Sep 3.
7
Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.每日口服4.8克(800毫克片剂)的缓释美沙拉嗪对中度活动性溃疡性结肠炎患者有效。
Gastroenterology. 2009 Dec;137(6):1934-43.e1-3. doi: 10.1053/j.gastro.2009.08.069. Epub 2009 Sep 18.
8
Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial.与每日2.4克(400毫克片剂)相比,每日4.8克(800毫克片剂)的缓释口服美沙拉嗪用于治疗轻度至中度活动性溃疡性结肠炎:ASCEND I试验。
Can J Gastroenterol. 2007 Dec;21(12):827-34. doi: 10.1155/2007/862917.
9
MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials.MMX多矩阵系统美沙拉嗪用于轻至中度溃疡性结肠炎患者诱导缓解:两项随机、双盲、安慰剂对照试验的联合分析。
Aliment Pharmacol Ther. 2007 Jul 15;26(2):205-15. doi: 10.1111/j.1365-2036.2007.03361.x.
10
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.每日一次高浓度美沙拉嗪缓释颗粒剂治疗活动期溃疡性结肠炎。
Gastroenterology. 2007 Jan;132(1):66-75; quiz 432-3. doi: 10.1053/j.gastro.2006.10.011. Epub 2006 Oct 12.

中重度溃疡性结肠炎的类固醇和 5-氨基水杨酸:解决困境。

Steroids and 5-aminosalicylic acids in moderate ulcerative colitis: addressing the dilemma.

机构信息

Department of Gastroenterology, The Henry Wellcome Laboratory, Institute of Translational Medicine, University of Liverpool, Nuffield Building, Crown Street, Liverpool L69 3GE, UK.

出版信息

Therap Adv Gastroenterol. 2013 Jan;6(1):33-8. doi: 10.1177/1756283X12461395.

DOI:10.1177/1756283X12461395
PMID:23320048
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3539295/
Abstract

Steroids have been a mainstay of ulcerative colitis (UC) therapy for many years, based on a thoroughly established efficacy profile for the induction of remission. However, in light of the considerable side effects and negative perceptions they carry, it is important to ensure such treatments are used as effectively as possible. For severe UC, the need for steroids is rarely questioned, and rightly so; it is for moderate UC that the role of steroids should be considered. Both patients and clinicians place a high importance on rapid, effective resolution of symptoms, yet at the same time wish to avoid unnecessary side effects. Through consideration of the available evidence, it becomes clear that both steroids and high-dose 5-aminosalicylic acid (5-ASA) are supported by robust trials demonstrating their efficacy. Indeed, both therapies have been shown to give rise to resolution of symptoms after 2 weeks in many patients. However, a paucity of head-to-head comparisons makes conclusive interpretation challenging. This paper therefore presents a practical approach, which builds on the available evidence and is developed from informed discussions with patients. This approach involves initiating therapy with high-dose 5-ASA, followed by a review of symptom improvements after 2-3 weeks. Steroids can then be introduced, when needed, with minimal delay. In this way, symptoms can be resolved rapidly, yet many patients may avoid unpleasant side effects.

摘要

类固醇已被广泛用于溃疡性结肠炎(UC)治疗多年,这主要基于其在诱导缓解方面的疗效。然而,鉴于其存在相当大的副作用和负面影响,确保这些治疗方法得到尽可能有效的应用至关重要。对于重度 UC,类固醇的需求很少受到质疑,这是正确的;对于中度 UC,应考虑使用类固醇。患者和临床医生都非常重视症状的快速、有效缓解,但同时希望避免不必要的副作用。通过对现有证据的考虑,很明显,类固醇和高剂量 5-氨基水杨酸(5-ASA)都得到了强有力的试验的支持,这些试验证明了它们的疗效。事实上,这两种治疗方法都在许多患者中显示出在 2 周后症状得到缓解。然而,由于缺乏头对头比较,使得结论解释具有挑战性。因此,本文提出了一种实用的方法,该方法基于现有证据,并通过与患者的知情讨论得出。这种方法包括起始高剂量 5-ASA 治疗,然后在 2-3 周后评估症状改善情况。然后在需要时尽快引入类固醇,尽量减少延迟。通过这种方式,可以快速缓解症状,但许多患者可能避免了不愉快的副作用。